arrow
S

Scott Berry

berry consultants llc
H指数:62
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating plasma ferritin and suPAR as treatable traits for critically ill patients with COVID-19 treated with anakinra: an exploratory analysis of the immune modulation domain of the REMAP-CAP randomised clinical trial

评估血浆铁蛋白和suPAR作为接受阿那白滞素治疗的危重症COVID-19患者的可治疗特征:REMAP-CAP随机临床试验免疫调节领域的探索性分析

2026-10-010
OAAI
Adaptive Platform Trials in Stroke

中风的适应性平台试验

STROKE
IF8.9
2025-01-010
PRE
Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke
2024-09-050
PRE
Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19
2023-04-0440
OA
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial
2023-01-0379
OA
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
2022-12-0112
OA
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection (Oct, 10.1007/s40265-022-01797-x, 2022)
DRUGS
IF14.4
2022-11-071
OAAI
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

RBX2660在PUNCH CD3中的疗效和安全性,这是一项III期,随机,双盲,安慰剂对照试验,采用贝叶斯主要分析来预防复发性艰难梭菌感染

DRUGS
IF14.4
2022-10-26131
OAAI
Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial
2022-02-152
PRE
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

新型冠状病毒肺炎恢复期血浆治疗与死亡率的关系: 一项随机临床试验的协作系统评价和荟萃分析

2021-11-2050
OAAI
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

新辅助T-DM1/帕妥珠单抗和紫杉醇/曲妥珠单抗/帕妥珠单抗治疗HER2乳腺癌的适应性随机I-SPY2试验

2021-11-0542
OAAI
Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study
2021-11-0133
OAAI
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
2021-10-0524
OA
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
2021-08-26569
OAAI